Several other research analysts have also issued reports on the stock. TheStreet lowered shares of Phibro Animal Health from a b- rating to a c+ rating in a report on Tuesday, September 10th. Morgan Stanley upgraded shares of Phibro Animal Health from an underweight rating to an equal rating and raised their price target for the stock from $21.00 to $30.00 in a report on Thursday, September 5th. They noted that the move was a valuation call. Credit Suisse Group restated a neutral rating and set a $25.00 price target (down previously from $31.00) on shares of Phibro Animal Health in a report on Wednesday, August 28th. ValuEngine upgraded shares of Phibro Animal Health from a sell rating to a hold rating in a report on Wednesday, October 2nd. Finally, Barclays lowered their price target on shares of Phibro Animal Health from $25.00 to $18.00 and set an underweight rating for the company in a report on Thursday, August 29th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating, one has given a buy rating and one has given a strong buy rating to the company’s stock. Phibro Animal Health has an average rating of Hold and an average target price of $26.60.
NASDAQ:PAHC opened at $24.26 on Wednesday. The firm’s 50 day simple moving average is $22.87 and its 200 day simple moving average is $26.55. The company has a debt-to-equity ratio of 1.84, a current ratio of 3.21 and a quick ratio of 1.77. Phibro Animal Health has a one year low of $20.00 and a one year high of $36.98. The company has a market cap of $986.65 million, a PE ratio of 18.48, a P/E/G ratio of 6.92 and a beta of 0.87.
Phibro Animal Health (NASDAQ:PAHC) last posted its earnings results on Monday, November 4th. The company reported $0.19 EPS for the quarter, missing the consensus estimate of $0.24 by ($0.05). Phibro Animal Health had a return on equity of 25.52% and a net margin of 4.99%. The business had revenue of $190.00 million for the quarter, compared to analyst estimates of $199.22 million. During the same quarter in the prior year, the business earned $0.39 earnings per share. The firm’s quarterly revenue was down 5.0% on a year-over-year basis. Equities research analysts expect that Phibro Animal Health will post 1.1 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 18th. Stockholders of record on Wednesday, November 27th will be paid a $0.12 dividend. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $0.48 annualized dividend and a dividend yield of 1.98%. Phibro Animal Health’s dividend payout ratio is currently 31.37%.
Several large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in shares of Phibro Animal Health by 2.9% in the 2nd quarter. Vanguard Group Inc. now owns 2,256,012 shares of the company’s stock valued at $71,673,000 after acquiring an additional 63,315 shares in the last quarter. Fiduciary Management Inc. WI grew its position in Phibro Animal Health by 332.3% in the 2nd quarter. Fiduciary Management Inc. WI now owns 1,073,390 shares of the company’s stock valued at $34,102,000 after purchasing an additional 825,090 shares during the period. Janus Henderson Group PLC grew its position in Phibro Animal Health by 315.4% in the 2nd quarter. Janus Henderson Group PLC now owns 956,784 shares of the company’s stock valued at $30,397,000 after purchasing an additional 726,444 shares during the period. Foresters Investment Management Company Inc. grew its position in Phibro Animal Health by 2.3% in the 2nd quarter. Foresters Investment Management Company Inc. now owns 671,558 shares of the company’s stock valued at $21,335,000 after purchasing an additional 14,972 shares during the period. Finally, State Street Corp grew its position in Phibro Animal Health by 0.3% in the 3rd quarter. State Street Corp now owns 653,400 shares of the company’s stock valued at $13,937,000 after purchasing an additional 1,638 shares during the period. Institutional investors own 49.94% of the company’s stock.
Phibro Animal Health Company Profile
Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition company primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture.
Read More: Equal Weight Rating
Receive News & Ratings for Phibro Animal Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Phibro Animal Health and related companies with MarketBeat.com’s FREE daily email newsletter.